Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics

Palo Alto, Calif June 15, 2004 Though there has been considerable biological and political debate over the use of embryonic stem cells (ESCs) vs. adult stem cells (ASCs) as therapies for tissue engineering and organ transplants, inherent benefits and drawbacks in both techniques compel them to coexist and complement each other.

"On the one hand, it's been very difficult to grow sufficient numbers of ASCs to regenerate tissues or create replacement organs," explains Technical Insights Research Analyst Katherine Austin. "On the other hand, ESCs provoke immune rejection much like any other transplant, and it's also been difficult to grow them in culture without mouse or other animal cells. These obstacles should be overcome in the near future, however."

It is possible to use a procedure called nuclear transplantation to replace the DNA of an embryonic stem cell with DNA from one of the patient's own cells, eliminating the problem of immune rejection. In another approach, differentiating small numbers of ESCs into blood cells and injecting them into the patient creates immune tolerance for other cells types derived from the ESCs, thereby reducing the intensity of rejection by the body.

ASCs, on the other hand, are patient derived and do not face the problem of immune rejection. However, for the most part they have not been as versatile as ESCs, exhibiting only those properties specific to their point of origin. For example, brain and hematopoietic stem cells give rise only to neural tissue and blood cells, respectively.

ASCs' presence in several mature tissues, including bone marrow, blood, adipose tissue, and the brain offsets their inability to differentiate into numerous types of tissues. Recent research has also detected rare ASCs that are 'pluripotent' and hence, capable of forming numerous cell types of the body.

Secondly, ASCs may be unsuitable for regeneration of damaged tissues in the case of elderly patients or due t

Contact: Julia Paulson
Technical Insights

Page: 1 2

Related biology news :

1. MSU group reviews Berkeley venture into brave new science funding world
2. Birds eye views earths magnetic lines
3. Digital X-ray microtomography yields stunning views of limb regeneration
4. New views of tropical thunderstorms and pollution effects on rainfall presented at AGU meeting
5. New MRI technology provides detailed views of brain development, response to injury
6. Study Reviews Medication Use In Elderly Cardiac Patients After Discharge
7. Sequential signals choreograph embryonic tubule formation
8. Therapeutic cloning no longer a dream, says scientist who produced first cloned embryonic stem cell
9. MIT technology jump-starts human embryonic stem cell work
10. New human embryonic stem-cell lines to be made available to researchers
11. Human embryonic stem cells may promise medical advances

Post Your Comments:

(Date:6/23/2020)... ... June 23, 2020 , ... Rigaku ... the next event in a series of TOPIQ webinars, which will cover the ... webinars was developed in response to social distancing measures that resulted in postponements ...
(Date:6/19/2020)... ... June 18, 2020 , ... ... Your Lab with Software for Data Decisions,” for pharmaceutical and biotech executives, ... integrate and automate cutting-edge scientific instruments and laboratory equipment from dozens of ...
(Date:6/11/2020)... ... June 08, 2020 , ... Cryo-Cell International’s announcement ... to protect workers in the medical field. The face masks will be distributed ... their lives every day to provide healthcare to pregnant women. The delivery of ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... June 25, 2020 , ... ... therapy for treating cancer, today announced the company has entered a license agreement ... The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the ... today that Derek Fournier has been appointed CEO and President. Founder and former ... immediately. , “DeCurtis Corporation has been on an incredible journey for the ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... today announced that it has filed an Investigational New Drug application (IND) with ... trial of its lead drug candidate NBTX-001 in patients with panic disorder (PD). ...
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... ... of Phase I of a Small Business Innovation Research (SBIR) program funded by ... 21st Century: Rapid Toxin Detection in the Field”. The project’s goal was to ...
Breaking Biology Technology:
Cached News: